Fig. 2: G4 ligand TMPyP4 hinders the development and progression of CRC. | Cell Death & Disease

Fig. 2: G4 ligand TMPyP4 hinders the development and progression of CRC.

From: Targeting G-quadruplex by TMPyP4 for inhibition of colorectal cancer through cell cycle arrest and boosting anti-tumor immunity

Fig. 2: G4 ligand TMPyP4 hinders the development and progression of CRC.The alternative text for this image may have been generated using AI.

a Representative images of colony formation in multiple human colorectal cancer cell lines HCT15, LST174T, RKO, SW620, NCI-H508, Caco2, and mouse colon cell line CT26 treated with the indicated concentrations of TMPyP4. b The line graph represents the relative colony formation of colorectal cancer cells treated with the indicated concentrations of TMPyP4. c Cell viability of colorectal cancer cells and normal cells was measured with the CCK8 assay. Cells were treated with TMPyP4 for 72 h. d, e Cells were treated with 4 μM or 8 μM TMPyP4 for 48 h. Then, the proportion of apoptotic cells was detected using annexin V-propidium iodide-based flow cytometry. Values are represented as mean ± SD, ****p ≤ 0.0001, by multiple t-tests. f, g Cell cycle analysis of colorectal cancer cells treated with or without TMPyP4 for 24 h. Cellular DNA content was determined by propidium iodide staining and flow cytometry. h, i The tumor size (h) and tumor weight (i) of nude mice bearing SW620 colorectal tumors treated with vehicle or 30 mg/kg TMPyP4. n = 6 mice for both groups. Values are represented as mean ± SD, ****p ≤ 0.0001, by unpaired t-test. j, k The tumor size (j) and tumor weight (k) of nude mice treated with vehicle or 30 mg/kg TMPyP4 in the PDX model. n = 6 mice for both groups. Values are represented as mean ± SD, ****p ≤ 0.0001, by two-way ANOVA (h, j) or unpaired t-test (i, k).

Back to article page